Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSP NASDAQ:IMTX NASDAQ:INDV NASDAQ:KNSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$46.54-2.1%$52.66$44.12▼$78.48$4.49B1.711.73 million shs1.39 million shsIMTXImmatics$9.08-2.3%$9.97$5.05▼$12.41$1.22B1.32339,194 shs290,488 shsINDVIndivior$40.53+0.0%$38.87$16.69▼$42.81$4.94B0.861.77 million shs837,410 shsKNSAKiniksa Pharmaceuticals International$62.84-0.3%$56.87$26.27▼$67.53$4.83B0.07957,375 shs619,956 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics0.00%-2.60%-13.78%-4.59%-31.70%IMTXImmatics0.00%-5.32%-4.62%-20.00%+40.78%INDVIndivior0.00%-0.02%-1.84%+21.87%+139.12%KNSAKiniksa Pharmaceuticals International0.00%-1.74%+10.46%+46.86%+131.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$46.54-2.1%$52.66$44.12▼$78.48$4.49B1.711.73 million shs1.39 million shsIMTXImmatics$9.08-2.3%$9.97$5.05▼$12.41$1.22B1.32339,194 shs290,488 shsINDVIndivior$40.53+0.0%$38.87$16.69▼$42.81$4.94B0.861.77 million shs837,410 shsKNSAKiniksa Pharmaceuticals International$62.84-0.3%$56.87$26.27▼$67.53$4.83B0.07957,375 shs619,956 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics0.00%-2.60%-13.78%-4.59%-31.70%IMTXImmatics0.00%-5.32%-4.62%-20.00%+40.78%INDVIndivior0.00%-0.02%-1.84%+21.87%+139.12%KNSAKiniksa Pharmaceuticals International0.00%-1.74%+10.46%+46.86%+131.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.58Moderate Buy$67.7845.63% UpsideIMTXImmatics 2.63Moderate Buy$20.80129.07% UpsideINDVIndivior 2.71Moderate Buy$43.677.74% UpsideKNSAKiniksa Pharmaceuticals International 3.00Buy$68.008.21% UpsideCurrent Analyst Ratings BreakdownLatest IMTX, INDV, CRSP, and KNSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/24/2026INDVIndivior Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)7/23/2026KNSAKiniksa Pharmaceuticals International The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $75.007/22/2026CRSPCRISPR Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform7/17/2026CRSPCRISPR Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/13/2026KNSAKiniksa Pharmaceuticals International Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$57.00 ➝ $74.007/9/2026INDVIndivior Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)7/8/2026CRSPCRISPR Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.007/6/2026CRSPCRISPR Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$80.006/29/2026INDVIndivior Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/29/2026KNSAKiniksa Pharmaceuticals International WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$59.00 ➝ $72.006/23/2026IMTXImmatics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$3.51M1,278.86N/AN/A$20.17 per share2.31IMTXImmatics$54.60M22.30N/AN/A$4.09 per share2.22INDVIndivior$1.24B3.99$2.72 per share14.90($0.78) per share-51.96KNSAKiniksa Pharmaceuticals International$677.56M7.14$0.79 per share79.17$7.44 per share8.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$581.60M-$6.22N/AN/AN/A-13,856.54%-25.66%-20.39%8/10/2026 (Estimated)IMTXImmatics-$222.26M-$1.99N/AN/AN/A-572.35%-47.36%-39.35%8/12/2026 (Estimated)INDVIndivior$210M$1.9520.789.49N/A19.44%-219.26%29.40%8/4/2026 (Estimated)KNSAKiniksa Pharmaceuticals International$59.01M$0.9069.8235.70N/A9.69%13.26%9.86%7/28/2026 (Estimated)Latest IMTX, INDV, CRSP, and KNSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2026Q2 2026IMTXImmatics-$0.4844N/AN/AN/A$11.73 millionN/A8/10/2026Q2 2026CRSPCRISPR Therapeutics-$1.1993N/AN/AN/A$7.45 millionN/A8/4/2026Q2 2026INDVIndivior$0.8890N/AN/AN/A$307.55 millionN/A7/28/2026Q2 2026KNSAKiniksa Pharmaceuticals International$0.30N/AN/AN/A$226.49 millionN/A5/12/2026Q1 2026IMTXImmatics-$0.42-$0.50-$0.08-$0.50$9.79 million$8.81 million5/4/2026Q1 2026CRSPCRISPR Therapeutics-$1.2185-$1.28-$0.0615-$1.28$6.06 million$1.46 million4/30/2026Q1 2026INDVIndivior$0.64$0.96+$0.32$3.45$272.84 million$317.00 million4/28/2026Q1 2026KNSAKiniksa Pharmaceuticals International$0.18$0.27+$0.09$0.27$206.11 million$214.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR Therapeutics0.3217.9717.96IMTXImmaticsN/A8.788.78INDVIndiviorN/A0.860.66KNSAKiniksa Pharmaceuticals InternationalN/A3.793.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%IMTXImmatics64.41%INDVIndivior60.33%KNSAKiniksa Pharmaceuticals International53.95%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics5.20%IMTXImmatics3.30%INDVIndivior0.74%KNSAKiniksa Pharmaceuticals International51.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics46096.45 million91.43 millionOptionableIMTXImmatics260134.07 million129.65 millionOptionableINDVIndivior1,051121.92 million121.02 millionNot OptionableKNSAKiniksa Pharmaceuticals International22076.94 million36.95 millionOptionableIMTX, INDV, KNSA, and CRSP HeadlinesRecent News About These CompaniesGranahan Investment Management LLC Cuts Position in Kiniksa Pharmaceuticals International, plc $KNSAJuly 25 at 6:23 AM | marketbeat.comSpruce Street Capital LP Has $36.65 Million Holdings in Kiniksa Pharmaceuticals International, plc $KNSAJuly 25 at 6:08 AM | marketbeat.comThe Goldman Sachs Group Increases Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target to $75.00July 25 at 2:24 AM | americanbankingnews.comKiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026July 23 at 6:47 PM | finance.yahoo.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $75.00 at The Goldman Sachs GroupJuly 23 at 12:35 PM | marketbeat.com5 Stocks With Recent Price Strength Despite Recent Market VolatilityJuly 23 at 9:25 AM | zacks.comRecent Price Trend in Kiniksa Pharmaceuticals International, plc (KNSA) is Your Friend, Here's WhyJuly 22, 2026 | zacks.comKiniksa Pharmaceuticals International (KNSA) Expected to Announce Quarterly Earnings on TuesdayJuly 21, 2026 | marketbeat.comBrokerages Set Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Target Price at $62.71July 17, 2026 | americanbankingnews.comKiniksa Pharmaceuticals: Leader In Pericarditis Merits Hold Rating After Recent GainsJuly 15, 2026 | seekingalpha.com4 Top-Ranked Stocks With Solid Net Profit Margins to Boost Your GainsJuly 14, 2026 | zacks.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price Expected to Rise, Wells Fargo & Company Analyst SaysJuly 13, 2026 | marketbeat.comKiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of "Buy" from AnalystsJuly 12, 2026 | marketbeat.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) Rating Lowered to Buy at Wall Street ZenJuly 12, 2026 | marketbeat.comKiniksa Pharmaceuticals International (KNSA) Joins Russell Indexes, Is The Upside Already Priced In?July 9, 2026 | finance.yahoo.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 12-Month High - Here's What HappenedJuly 6, 2026 | marketbeat.comKiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's WhyJuly 6, 2026 | zacks.comPeregrine Capital Management LLC Sells 29,550 Shares of Kiniksa Pharmaceuticals International, plc $KNSAJuly 1, 2026 | marketbeat.comInspire Investing LLC Makes New $1.70 Million Investment in Kiniksa Pharmaceuticals International, plc $KNSAJuly 1, 2026 | marketbeat.comPictet Asset Management Holding SA Sells 164,232 Shares of Kiniksa Pharmaceuticals International, plc $KNSAJuly 1, 2026 | marketbeat.comWhat Makes Kiniksa Pharmaceuticals International, plc (KNSA) a Strong Momentum Stock: Buy Now?June 30, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMTX, INDV, KNSA, and CRSP Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$46.54 -0.99 (-2.08%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$46.98 +0.44 (+0.95%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Immatics NASDAQ:IMTX$9.08 -0.21 (-2.26%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$9.09 +0.01 (+0.11%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Indivior NASDAQ:INDV$40.53 +0.02 (+0.05%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$40.52 -0.01 (-0.01%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Kiniksa Pharmaceuticals International NASDAQ:KNSA$62.84 -0.21 (-0.33%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$62.79 -0.05 (-0.08%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
